Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
1,460
Total Claims
$5.4M
Drug Cost
242
Beneficiaries
$22K
Cost/Patient
Risk Score Breakdown 7/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
+157%
Opioid rate vs peers
16.1% vs 6.3% avg
+65%
Cost per patient vs peers
$22K vs $14K avg
+91%
Brand preference vs peers
27.9% vs 14.6% avg
Opioid Prescribing
16.1%
Opioid Rate
235
Opioid Claims
$12K
Opioid Cost
42.1%
Long-Acting Rate
Brand vs Generic
Brand: 407 claims · $5.3M
Generic: 1,053 claims · $160K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Palbociclib | 71 | $1.1M |
| Lenalidomide | 28 | $509K |
| Cabozantinib S-Malate | 17 | $424K |
| Ibrutinib | 27 | $423K |
| Venetoclax | 27 | $422K |
| Abemaciclib | 19 | $311K |
| Enzalutamide | 21 | $252K |
| Olaparib | 13 | $250K |
| Nilotinib Hcl | 12 | $242K |
| Dasatinib | 12 | $220K |
| Abiraterone Acetate | 38 | $121K |
| Apixaban | 32 | $39K |
| Lipase/Protease/Amylase | 19 | $35K |
| Morphine Sulfate | 82 | $2,503 |
| Letrozole | 82 | $2,007 |
Prescribing Profile
Patient Profile
73
Avg Age
65%
Female
2.24
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data